News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

HIV treatment takes two steps forward

Media release November 1, 2006

HIV treatment takes two steps forward

A once-a-day medicine to attack the HIV/AIDS virus is part of a package of treatments for people with HIV announced by Pharmac today.

Atazanavir (Reyataz) is a once a day HIV protease inhibitor which has the advantage of having fewer metabolic side effects than other protease inhibitor drugs. These side effects can can cause complications like heart disease.

The other part of the package is the listing of pravastatin (Pravachol), a cholesterol-lowering drug that can be used to correct metabolic side effects in people with HIV who are being treated with protease inhibitors. Two statins are already funded, atorvastain and simvastatin. However, pravastatin is the only one that can be used in combination with HIV protease inhibitors.

Both treatments will be funded from today (1 November 2006).

PHARMAC Medical Director Dr Peter Moodie says the two drugs provide the opportunity to advance treatment for HIV patients.

“By and large people can manage their HIV well with the drug treatments that are available,” Dr Moodie says. “It is not uncommon, though, for people who are taking protease inhibitors to have metabolic complications such as increased triglyceride and cholesterol levels. These can lead to an increased risk of heart disease so these funding decisions provide welcome new treatment options,” Dr Moodie says.

“Having a once-a-day protease inhibitor will mean that people who might find it difficult to take all their medicines in one day will have a better treatment option.”

Dr Moodie says the decision to subsidise atazanavir will benefit an estimated 40-50 people with HIV each year. About 30 people would benefit from pravastatin.

Atazanavir will join five other fully subsidised HIV protease inhibitors. Another treatment for HIV/AIDS, enfuvirtide, has also been funded recently.


ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>


Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>

ALSO:

Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
Jenny Abrahamson's John & Charles Enys: Castle Hill Runholders, 1864-1891

This volume will be of interest to a range of readers interested in the South Island high country, New Zealand’s natural environment, and the history of science. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION